Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 sep 2007 - 14:24
Statutaire naam
Crucell N.V.
Titel
CORRECTION - Impact of discontinuation of Merck HIV study on Crucell’s prospects
Bericht
Leiden, The Netherlands, September 25 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today stated that it wishes to emphasize that the discontinuation of Merck’s HIV phase I and II studys, as announced on Friday September 21, is not related to the use of Crucell’s PER.C6® technology. The company further added that it reiterates its revenue guidance for 2007 at € 220 to 225 million.
Gerelateerde downloads
Datum laatste update: 18 april 2026